Главная »» Science articles of world periodical [1998 - 2003] »» O »» Oncol Rep
версия для печати
Vollmers HP. Zimmermann U. Krenn V. Timmermann W. Illert B. Hensel F. Hermann R. Thiede A. Wilhelm M. Ruckle-Lanz H. Reindl L. Muller-Hermelink HK.
Institut fur Pathologie, Josef-Schneider-Str. 2, Wurzburg, 97080, Germany.
In a first clinical trial with the apoptosis-inducing human antibody SC-1 eight patients with poorly differentiated stomach adenocarcinoma of diffuse-type received 20 or 30 mg of purified SC-1 antibody intravenously, followed 24 or 48 h later by gastrectomy and lymphadenectomy. In seven cases a significant induction of apoptotic activity was measured in primary tumors as compared with earlier biopsy material and in five patients a significant regression of tumor mass could be determined histopathologically. No toxic crossreactivity was observed with normal tissue or organs of patients.